Copeptin associates with major adverse cardiovascular events in patients on maintenance hemodialysis.
Clin Chim Acta
; : 119937, 2024 Aug 20.
Article
en En
| MEDLINE
| ID: mdl-39173701
ABSTRACT
BACKGROUND:
End-stage renal disease (ESRD) necessitating hemodialysis pose substantial cardiovascular risks, with cardiovascular disease (CVD) as a leading cause of mortality. Biomarkers like copeptin have emerged as potential indicators of cardiovascular stress and prognosis in CKD populations.OBJECTIVE:
This study aimed to assess the prognostic value of copeptin in predicting major adverse cardiovascular events (MACEs) among hemodialysis patients, alongside traditional cardiac biomarkers.METHODS:
ESRD patients undergoing maintenance hemodialysis were enrolled. Copeptin levels were measured, and patients were followed for MACEs, defined as cardiovascular deaths, myocardial infarction, stroke, or heart failure-related hospitalizations. Cox proportional-hazards models were used to evaluate the association between copeptin and outcomes, adjusting for relevant covariates.RESULTS:
Among 351 patients followed for a median of 22.7â¯months, elevated copeptin levels were significantly associated with an increased risk of MACEs (HR 1.519, 95â¯% CI 1.140 to 2.023; pâ¯=â¯0.00425). Copeptin demonstrated predictive capability across multiple statistical tests (Log-rank pâ¯=â¯0.024; Gehan pâ¯<â¯0.001; Tarone-Ware pâ¯<â¯0.001; Peto-Peto pâ¯=â¯0.027), although significance was attenuated in pairwise comparisons post-adjustment for multiple testing. Combining copeptin with NT-proBNP or hs-cTnT further enhanced risk stratification for MACEs.CONCLUSION:
Elevated copeptin levels independently predict adverse cardiovascular outcomes in hemodialysis patients. Integrating copeptin with traditional cardiac biomarkers may refine risk stratification and guide personalized therapeutic strategies in this high-risk population.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Clin Chim Acta
Año:
2024
Tipo del documento:
Article